Despite the setbacks successes have been achieved. Of the 18 SCID patients treated for their life threatening condition, 17 are still alive and have had a healthy, functioning immune system for up to five years and a good quality of life. In addition to monogenic conditions, gene therapy also represents a viable treatment for multigenic disorders, such as cancer, either as a standalone treatment or in combination with chemotherapy or radiotherapy. A huge amount of work is yet to be done, but with efficient monitoring of trials and continuous improvements of viral vectors, gene therapy may still represent an important addition to the treatment armamentarium for a range of diseases.

1 BBC Online News. "Bubble boy" saved by gene therapy. 3 April 2002, http://news.bbc.co.uk/1/hi/health/1906999.stm (accessed 20 Aug 2004).
2 Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72:
3 Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-3..
4 Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-9.
5 Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genet 2000;24:257-61.
6 Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401517-8.
7 Kay MA, Nakai H. Looking into the safety of AAV vectors. Nature 2003;424:251.
8 Bushman F. Targeting retroviral integration. Mol Ther 2000;6.
9 Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP. Site-specific genomic integration produces therapeutic factor IX levels in mice. Nature Biotech 2002;20:1124-8.
10 Ries, S and Kirn, W M. ONYX-015: mechanisms of action and clinical potential of a replication selective adenovirus. Br J Cancer 2002;86:5-11.
11 Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004;427:779-81.

Lesson of the week
Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America

Sukhbir Ahluwalia, Stephen D Lawn, Jeevendra Kanagalingam, Henry Grant, Diana N J Lockwood

Mucocutaneous leishmaniasis may be acquired by travellers to central and South America

Royal National Throat, Nose and Ear Hospital, London
Sukhbir Ahluwalia
senior house officer
Jeevendra Kanagalingam
specialist registrar
Henry Grant
consultant surgeon

Hospital for Tropical Diseases, London
Stephen D Lawn
specialist registrar
Diana N J Lockwood
consultant physician

Correspondence to:
S D Lawn, Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT
stevelawn@yahoo.co.uk

Leishmaniasis is caused by protozoan parasites belonging to the genus *Leishmania*.[1][2] The infection is transmitted by phlebotomine sandflies, and a wide range of domestic and wild vertebrates and humans serve as reservoirs of infection. Leishmaniasis is endemic throughout the Middle East, north Africa, parts of Europe, and central and South America.[1][2] The worldwide prevalence is 12 million, with a tenth of the world's population at risk.

The infecting *Leishmania* species determines the clinical presentation of disease, of which there are three dominant clinical forms: cutaneous leishmaniasis, mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis.[1][2] Mucocutaneous disease is a chronic inflammatory process involving the nasal, pharyngeal, and laryngeal mucosa, which can lead to extensive tissue destruction. MCL develops as a complication of cutaneous leishmaniasis, parasites disseminating from the primary cutaneous lesion via lymphatic vessels and blood to reach the upper respiratory tract mucosa. Such metastatic spread more commonly occurs with species belonging to the *L viannia* subgenus (formerly known as the *L braziliensis* complex), which are present in tropical forested areas of central and South America.[1][2] MCL is estimated to develop as a complication of *L viannia* cutaneous leishmaniasis in 5-20% of untreated patients living in areas where leishmaniasis is endemic.[3]

Over the past 20 years, "exotic" foreign travel from the United Kingdom has increased, resulting in more cases of imported tropical infections. Increased awareness of such diseases is important as early recognition and treatment may improve outcome. Here we describe three healthy British travellers who developed MCL after travelling to Latin America. Each was managed jointly at the Hospital for Tropical Diseases in London by tropical medicine physicians and otorhinolaryngologists. We emphasise the importance of a history of travel to Latin America in patients presenting with unusual skin lesions or chronic nasopharyngeal symptoms and describe the diagnostic process.

Fig 1 Patient with mucocutaneous leishmaniasis showing granulomatous lesion of septum (left); lesions on nasal alae (centre); nasal alae after treatment (right)

Case reports

Case 1

A month after a holiday in South America, a 38 year old man was investigated at a regional centre for infectious and tropical diseases for a persistent cutaneous ulcer on his buttock and associated inguinal lymphadenopathy. Biopsies failed to establish a diagnosis, and, as the lesion was healing, the patient was discharged. Nine months later, however, the patient developed nasal congestion that persisted for six months until he developed lesions on the exterior of his nose (fig 1, left). Examination of the nasal mucosa showed a granulomatous lesion of the septum (fig 1, centre), and mucosal biopsies were obtained under topical anaesthesia. No parasites were found on microscopy or culture, but DNA of *L viannia* parasites was detected using polymerase chain reaction, confirming a diagnosis of MCL. He was treated with intravenous sodium stibogluconate and made a full recovery (fig 1, right).

Case 2

A month after a school trip to Belize, a 17 year old woman developed persistent erythema and swelling of the nasal tip and rhinorrhoea. She was treated as an inpatient at her local hospital with intravenous antibiotics for suspected low grade bacterial cellulitis. After referral to the Hospital for Tropical Diseases, cutaneous and mucosal biopsies were negative on microscopy and culture but polymerase chain reaction was positive for *L viannia* DNA, establishing a diagnosis of MCL. She was successfully treated with sodium stibogluconate.

Case 3

A 19 year old woman consulted her general practitioner shortly after returning from extensive travels in rural South America, complaining of persistent skin ulcers and nasal congestion. Her doctor contacted the Hospital for Tropical Diseases immediately concerned that her patient might have MCL. A differential diagnosis of Wegener's granulomatosis was considered as the patient was known to have serum antinuclear antibodies. Clinical examination showed florid inflammation of the nasal and oropharyngeal mucosa and five cutaneous ulcers with raised margins. Diagnoses of cutaneous leishmaniasis and MCL were established by positive culture and polymerase chain reaction of mucosal and cutaneous biopsies. She was successfully treated with intravenous sodium stibogluconate.

Discussion

Mucocutaneous leishmaniasis is reported infrequently among travellers returning from Latin America to countries where the disease is not endemic.[4–9] The cases described here were all young healthy travellers who had spent time in tropical forest areas of Latin America; none had any risk factors for HIV infection. MCL is endemic in such areas between southern Mexico and the northern tip of Argentina.[2] The trend towards "adventure travel" to Latin America may lead to MCL being more often imported to the United Kingdom. Patients with MCL may present to a wide variety of clinicians, including general practitioners, all of whom should be aware of the potential significance

Fig 2 A 4 cm diameter cutaneous leishmaniasis ulcer on lower leg caused by *L viannia* subgenus species showing the typical raised, indurated margin

of a history of rural travel in Latin America. Familiarity with the manifestations of cutaneous leishmaniasis and MCL may speed diagnosis and limit disease progression.

Recognition of cutaneous leishmaniasis lesions may help to prevent development of MCL or facilitate diagnosis of established MCL. The disease can be prevented by treating *L viannia* cutaneous leishmaniasis before mucosal involvement. Alternatively, in patients with established mucosal disease, the presence of cutaneous leishmaniasis (or a history suggestive of a previous self healing cutaneous leishmaniasis lesion) may provide a strong clue to a diagnosis of mucocutaneous disease.

Cutaneous leishmaniasis lesions often develop on exposed parts of the body within a few weeks of exposure to infected sandfly bites. Single or multiple ulcers typically have a raised, indurated margin and a sloughy base (fig 2). There may be satellite lesions (sporotrichoid spread) and cord-like infiltration of proximal lymphatic vessels and local lymphadenopathy.

Box 1: Differential diagnosis for nasal congestion

- Rhinitis (allergy)
- Anatomical cause (septal deviation, hypertrophic turbinates)
- Hormonal disorder (puberty, pregnancy, hypothyroidism, acromegaly)
- Granulomatous disease (sarcoidosis, Wegener's granulomatosis)
- Drug induced cause (rhinitis medicamentosa, prazosin, cocaine)
- Impaction (crusts, foreign body)
- Mass (adenoids, nasal polyps, nasopharyngeal carcinoma)
- Infection (leishmaniasis, tuberculosis, leprosy, syphilis, rhinoscleroma, coccidioidomycosis, histoplasmosis, blastomycosis)

The differential diagnosis for cutaneous leishmaniasis includes secondary infected insect bites, sporotrichosis (a fungal infection implanted into the skin by a thorn or other penetrating injury), or more rarely cutaneous tuberculosis. Appropriate drug treatment promotes rapid healing of cutaneous leishmaniasis lesions, but the great majority will heal spontaneously over several months; such healing, however, does not preclude the later development of MCL, as illustrated by case 1.

The most common symptom of MCL is persistent nasal congestion, for which the differential diagnosis is broad (box 1). Anterior nasal septal granulomas may be visible with a light source and Thudicum's speculum, whereas posteriorly located granulomas require nasendoscopy to be seen. Progressive MCL lesions destroy upper respiratory tract mucosa over months and years. Common sites are the turbinates and nasal septum,[7][9] where erosion of underlying tissue and cartilage may result in perforation. Progressive tissue destruction at the nasal mucocutaneous junction in advanced disease may cause marked disfigurement, requiring reconstructive surgery. Lesions may also affect the palate, pharynx, and larynx, causing palatal dysfunction, dysphagia, dysphonia, and aspiration.[1][2] Bony structures are not involved.

Diagnoses of cutaneous leishmaniasis and MCL are established by demonstrating the presence of *Leishmania* parasites in infected tissues. Serology is rarely helpful except in advanced MCL. Punch biopsies should be taken from the raised, indurated edge of cutaneous leishmaniasis lesions and sent fresh for microbiological and parasitological examination and in formalin for histopathological assessment. Examination of Giemsa stained impression smears for the presence of the intracellular form of the parasites (amastigotes) may quickly yield a diagnosis in some patients. Amastigotes may also be seen in histopathological sections. The flagellate form of the parasite (promastigote) may be cultured from biopsies on modified Novy-McNeal-Nicolle medium incubated for up to three weeks.

Polymerase chain reaction is the most sensitive diagnostic test, however, and is also used to differentiate *L viannia* subgenus infections, which are associated with the greatest risk of MCL.[10][11] Similarly, in patients with suspected MCL, biopsies of mucosal lesions are required for diagnosis, and additional biopsies may be taken from the turbinates even if these are not overtly involved. Histopathology of mucosal biopsies shows granulomatous changes for which the differential diagnosis is broad (box 2). Compared with cutaneous leishmaniasis, *Leishmania* parasites are less readily visualised or cultured from MCL lesions because the vigorous host response limits the tissue parasite burden. In recent years, however, polymerase chain reaction has proved to be a sensitive tool.[11]

> **Box 2: Differential diagnosis for nasal granulomas**
>
> - Bacterial infection (tuberculosis, leprosy, syphilis, rhinoscleroma)
> - Fungal infection (coccidioidomycosis, histoplasmosis, blastomycosis, rhinosporidiosis)
> - Parasitic infection (leishmaniasis)
> - Autoimmune (Wegener's granulomatosis, systemic lupus erythematosis)
> - Sarcoidosis
> - Lymphoma
> - Foreign body
> - Heavy metals (beryllium, nickel)
> - Idiopathic cause

MCL requires prolonged parenteral treatment with pentavalent antimonials (treatment of choice) or amphotericin preparations. Such treatment is associated with toxicity and risk of relapse.[1][2] Patients require joint management from infectious or tropical diseases physicians plus otorhinolaryngologists who have clinical experience of MCL and access to the necessary specialist laboratory investigations. Expeditious and appropriate care, however, can be given only after the diagnosis has been suspected.

1 Herwaldt BL. Leishmaniasis. *Lancet* 1999;354:1191-9.
2 Dedet JP, Pratlong F. Leishmaniasis. In: Cook GC, Zumla A, eds. *Manson's tropical diseases.* 21st ed. London: Saunders, 2003:1339-64.
3 David C, Dimier-David L, Vargas F, Torrez M, Dedet JP. Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study. *Trans R Soc Trop Med Hyg* 1993;87:7-9.
4 Rosbotham JL, Corbett EL, Grant HR, Hay RJ, Bryceson AD. Imported mucocutaneous leishmaniasis. *Clin Exp Dermatol* 1996;21:288-90.
5 Scope A, Trau H, Bakon M, Yarom N, Nasereddin A, Schwartz E. Imported mucosal leishmaniasis in a traveler. *Clin Infect Dis* 2003;37:e83-7.
6 Costa JW Jr, Milner DA Jr, Maguire JH. Mucocutaneous leishmaniasis in a US citizen. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003;96:573-7.
7 Lohuis PJ, Lipovsky MM, Hoepelman AI, Hordijk GJ, Huizing EH. Leishmania braziliensis presenting as a granulomatous lesion of the nasal septum mucosa. *J Laryngol Otol* 1997;111:973-5.
8 Singer C, Armstrong D, Jones TC, Spiro RH. Imported mucocutaneous leishmaniasis in New York city. Report of a patient treated with amphotericin B. *Am J Med* 1975;59:444-7.
9 Galioto P, Fornaro V. A case of mucocutaneous leishmaniasis. *Ear Nose Throat J* 2002;81:46-8.
10 De Bruijn MHL, Barker DC. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. *Acta Tropica* 1992;52:45-58.
11 Pirmez C, da Silva Trajano V, Paes-Oliveira Neto M, da-Cruz AM, Goncalves-da-Costa SC, Catanho M, et al. Use of PCR in diagnosis of human American tegumentary leishmaniasis in Rio de Janeiro, Brazil. *J Clin Microbiol* 1999;37:1819-23.

(Accepted 14 June 2004)

Interactive case report

A 35 year old woman with diabetic nephropathy who wants a baby

This case was described on 18 and 25 September (*BMJ* 2004;329: 674, 729). Debate on the management of the patient continues on bmj.com (http://bmj.com/cgi/eletters/329/7468/729). On 16 October we will publish the outcome of the case together with commentaries on the issues raised by the management and online discussion from the patient and relevant experts.